viewAnteris Technologies Ltd

Admedus secures regulatory approval in Canada for heart tissue products

The company's shares are trading 4% higher intra-day, at $0.26.

A human heart
Canada is the second market to have access to this technology

Admedus Ltd (ASX:AHZ) has received regulatory approval to introduce its CardioCel 3D® and VascuCel® products in Canada, alongside CardioCel® which is already available.

CardioCel 3D is a shaped tissue product representing a disruptive technology in the high-complexity congenital defect repair space.

WATCH: Admedus Ltd moving up the value chain and preparing for 'pivotal' year

Wayne Paterson, chief executive officer, said: “We welcome today’s announcement and are pleased to be able to expand our product offering in Canada, giving physicians and patients access to the numerous health benefits of our latest clinically-superior technology.

“This opportunity presents Admedus with a valuable opportunity to move up the value chain and increase our presence and market share in North America.”

Unique product mimics the characteristics of normal human tissue

CardioCel 3D offers patients the long-term health benefits of Admedus’ ADAPT® technology.

ADAPT treated tissue has been proven to more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response and improved tissue ingrowth.

CardioCel 3D’s pre-shaped curve provides physicians access to an optimised arch reconstruction solution with non-antigenic response and unique calcification resistance.

CardioCel 3D and VascuCel are already sold in the U.S.

CardioCel 3D is the latest product from Admedus’ proprietary ADAPT portfolio and was officially launched in the U.S. on 1 February 2018.

Canada is the second market to have access to this technology.

Admedus’ VascuCel scaffold is also bioengineered using the ADAPT technology and provides enhanced procedural efficiency for a broad spectrum of vascular surgical procedures.

READ: Admedus introduces heart tissue technology to India

The company recently introduced its ADAPT engineered tissue technology to India, a country with circa 50 million cardiac patients and 280,000 babies born annually with a congenital heart defect.

ADAPT achieved sales revenue of $2.1 million for the December 2017 quarter, up 18% on the previous quarter, largely driven by increased sales in the European and emerging markets regions.

Quick facts: Anteris Technologies Ltd

Price: 3.67 AUD

Market: ASX
Market Cap: $21.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a...

on 19/10/20

2 min read